• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Silo Pharma Inc.

    9/18/24 4:17:30 PM ET
    $SILO
    Apparel
    Consumer Discretionary
    Get the next $SILO alert in real time by email
    DEFA14A 1 ea0214566-04.htm ADDITIONAL DEFINITIVE SOLICITING MATERIALS.

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    _________________________________

    Schedule 14A

    _________________________________

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No.    )

    Filed by the Registrant

     

    ☒

    Filed by a Party other than the Registrant

     

    ☐

    Check the appropriate box:

    ☐

     

    Preliminary Proxy Statement

    ☐

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

     

    Definitive Proxy Statement

    ☒

     

    Definitive Additional Materials

    ☐

     

    Soliciting Material under § 240.14a-12

    SILO PHARMA, INC.
    (Name of Registrant as Specified In Its Charter)

    ______________________________________________________________

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

     

    No fee required

    ☐

     

    Fee paid previously with preliminary materials.

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

     

    SILO PHARMA, INC. c/o WCST Proxy Services 721 N. Vulcan Ave. Ste. 106 Encinitas, CA 92024 TIME SENSITIVE SHAREHOLDER INFORMATION ENCLOSED IMPORTANT NOTICE CONTROL NUMBER: REGARDING THE AVAILABILITY OF PROXY MATERIALS Pursuant to Securities and Exchange Commission rules, you are receiving this Notice that the proxy materials for the Annual meeting are available on the Internet. Follow the instructions below to view the materials and vote or request printed copies. Exercise Your Right to Vote Meeting Type: Annual meeting of Stockholders For Holders as of: September 13, 2024 Date: November 12, 2024 Time: 11:00 A.M. Eastern Time Location: 677 N Washington Boulevard, Sarasota, Florida 34236 ---BEFORE YOU VOTE --- How To View Or Request Paper Copies Of Our Materials PHONE: Call 1-619-664-4780 FAX: Send this card to 760-452-4423 View Materials Online Via The Internet: Https://Www.Westcoaststocktransfer.Com/Proxy-Silo/ And Follow The On-Screen Instructions. Email: [email protected] Include Your Control Id In Your Email. If You Want To Receive A Paper Copy Of The Proxy Materials You Must Request One. There Is No Charge To You For Requesting A Copy. To Facilitate Timely Delivery Please Make The Request, As Instructed Above, Before October 28, 2024. This communication represents a notice to access a more complete set of proxy materials available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement is available at: https://www.westcoaststocktransfer.com/proxy-silo/ ---HOW TO VOTE--- Vote By Internet To vote by internet, go to https://www.westcoaststocktransfer.com/proxy-SILO/ before 11:59 p.m. Eastern Time on November 11, 2024 using the control number shown at the upper right corner of this notice. Vote In Person If you choose to vote these shares in person at the meeting, you must request a paper copy of the materials which will include a proxy card. Vote By Mail You can vote by mail by requesting a paper copy of the materials which will include a voting instruction form. The purposes of this meeting are as follows: 1. To elect four (4) members to the Board of Directors to serve for a one-year term to expire at the 2025 annual meeting of shareholders; 2. To ratify the appointment of Salberg & Company, P.A. as our independent registered public accounting firm for the fiscal year ending December 31, 2024.; 3. To approve, by non-binding advisory vote, the resolution approving named executive officer compensation.; 4. To approve, by non-binding advisory vote, the frequency of future non-binding advisory votes on resolutions approving future named executive officer compensation.; and 5. To authorize the adjournment of the Annual Meeting if necessary or appropriate, including to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the foregoing proposals. The board of directors has fixed the close of business on September 13, 2024 as the record date for the determination of stockholders entitled to receive notice of the Annual Meeting and to vote the shares of our common stock. they held on that date at the meeting or any postponement or adjournment of the meeting. Please note - This is not a Proxy Card - you cannot vote by returning this card

     

    Get the next $SILO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SILO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SILO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $4,847 worth of shares (12,000 units at $0.40), increasing direct ownership by 6% to 209,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/20/25 4:00:32 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

    Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a non-binding Letter of Intent ("LOI") with Allucent (US) LLC ("Allucent"), a global clinical research organization (CRO), to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy subject

    12/30/25 8:05:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD

    SARASOTA, FL, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Allucent, a global full-service clinical research organization (CRO), to support the Company's final preparations and planned submission of its investigational new drug application (IND) to the FDA for a Phase 1 clinical trial of its intranasal prophylactic SPC-15 as a treatment for PTSD. The Company currently expects to submit the IND in 2026 and commence its first-in-human (FIH) SPC-15 trial subsequent to FDA approval. "We believe that a partnership with All

    11/17/25 8:05:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain

    Investment vehicle provides diversified exposure to real-world assets and expected to reduce portfolio volatility Strategic allocation aligns with Silo's objective of generating yield while maintaining a hedge against downside risk New York, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Alphaledger/Simplify Target 12% Distribution Fund LLC (the "Alphaledger T12 Fund") as a core component of its real-world asset (RWA) investment strategy on the Solana blockchain. This strategic allocation aligns with Silo's approac

    10/29/25 8:25:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $4,847 worth of shares (12,000 units at $0.40), increasing direct ownership by 6% to 209,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/20/25 4:00:32 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    SEC Filings

    View All

    Silo Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Silo Pharma, Inc. (0001514183) (Filer)

    12/29/25 9:04:03 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form EFFECT filed by Silo Pharma Inc.

    EFFECT - Silo Pharma, Inc. (0001514183) (Filer)

    11/28/25 12:15:18 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form 424B3 filed by Silo Pharma Inc.

    424B3 - Silo Pharma, Inc. (0001514183) (Filer)

    11/26/25 4:15:51 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Financials

    Live finance-specific insights

    View All

    Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

    Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was

    10/6/25 8:10:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Leadership Updates

    Live Leadership Updates

    View All

    Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

    Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

    8/5/25 8:32:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Silo Pharma Inc.

    SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

    7/26/24 4:17:36 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form SC 13G filed by Silo Pharma Inc.

    SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

    6/13/24 5:08:53 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

    SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)

    1/25/24 5:27:04 PM ET
    $SILO
    Apparel
    Consumer Discretionary